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OBJECTIVES: The purpose of this study was to examine
the economic and quality of life (QoL) impact of seasonal
allergic conjunctivitis (SAC) in Oxfordshire, England.
METHODS: The inclusion criteria for cases were that
participants: 1) experienced itchy, bloodshot and water-
ing eyes at some time between February and August every
year since 1999, and 2) considered it likely that this was
in response to seasonal allergens. Controls were drawn
from the same sources and were age and sex-matched 
to cases. Participants completed the EQ-5D Health 
Questionnaire, the Rhinoconjunctivitis Quality of Life
Questionnaire, the National Eye Institute (US) Visual
Functioning Questionnaire 25, and a specially developed
Health Economic and Demographic Questionnaire.
RESULTS: Most participants in both groups were female
(67.5% in SAC and 70% in control group, P = 0.565).
Weekly earnings were lower in the SAC group (P <
0.001), as the SAC group also worked fewer hours per
week (P < 0.001). Participants with SAC also experienced
a greater degree of pain and discomfort as measured by
the EQ-5D (P = 0.018) and a lower perception of their
health status using the EQ-VAS (P = 0.039). Statistically
signiﬁcant differences between both groups were detected
in all domains of the VFQ-25, except general and colour
vision, although differences were thought to be clinically
signiﬁcant only for the ocular pain domain. The RQLQ
scores were also all found to differ signiﬁcantly between
groups (P < 0.001). The total of both the public health
care and private out-of-pockets costs of SAC in our study
population ranged on average between £64.61 for a pen-
sioner to £142.29 for a person with SAC in paid employ-
ment. CONCLUSIONS: SAC is a costly, highly prevalent,
chronic condition associated with signiﬁcant reductions
in both ocular and general quality of life, as well as
ongoing out-of-pocket expenses and health care costs.
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OBJECTIVES: The EAPIQ was developed based on a
pilot study conducted in the US and focus groups with
eye allergy sufferers in Europe. The purpose of this study
is to present the results of the EAPIQ’s construct valid-
ity and reliability testing. METHODS: A total of 146
patients from 2 allergy clinics completed the EAPIQ twice
over a two-week period during the fall and winter allergy
seasons, along with concurrent measures of health status,
work productivity, and utility. Construct validity, 
reliability and known groups validity were assessed.
RESULTS: Results from the validation study suggested
the deletion of 14 items that required patients to com-
plete the percentage of time they were troubled by some-
thing (daily activity limitations/emotional troubles).
These questions yielded a signiﬁcant amount of missing
or inconsistent data (50%). The resulting factor analysis
suggested four domains: symptoms, daily activity limita-
tions, emotional well-being, and treatment satisfaction.
The relative merits of assessing symptom-bother sepa-
rately from symptom-frequency were also assessed.
Results indicated that the two scales were highly corre-
lated (>0.9) and known groups validity testing suggested
the superior discriminative ability of the symptom fre-
quency measure (F = 44.63 vs 39.63). However, when
symptom bother and frequency items were summated dis-
criminative validity was superior (F = 45.29). As a result,
it was decided to sum the symptom bother and frequency
items. All items met the tests for item convergent validity
(item-scale correlation >=0.4). The success rate for item
discriminant validity testing was 97% (item-scale corre-
lation greater with own scale than with any other). Inter-
nal consistency reliability criterion (>=0.7) were met for
all scales (range 0.89–0.93). Ongoing work will assess the
test-retest reliability and known groups’ validity of the
EAPIQ. CONCLUSIONS: Asking patients to write in
responses can lead to inconsistent responses or missing
data. With the deletion of those items, the EAPIQ 
was found to have satisfactory construct validity and 
reliability.
EYE DISEASES OR DISORDERS
EYE DISEASES OR DISORDERS—Clinical
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OBJECTIVES: To estimate the prevalence of low vision
(LV) and blindness in France. METHODS: Two national
surveys were pooled together: 1) 2075 institutions (for
children or adults with handicaps, the aged, and psychi-
atric centers) were selected at random from the French
Health Ministry ﬁles in 18 predeﬁned strata. Of the
